Publication of Report & Accounts and Notice of AGM

RNS Number : 5660H

ValiRx PLC

31 May 2011

 



31 May 2011

ValiRx Plc

("ValiRx" or "the Company")

Publication of Report & Accounts and Notice of AGM

ValiRx Plc (AIM: VAL), a life science company with a focus on cancer diagnostics and therapeutics for personalised medicine, gives notice that its Report and Accounts for the year ended 31 December 2010 have been posted to shareholders today together with a notice of its Annual General Meeting ("AGM") to be held at 10:00 a.m. on 23 June 2011 at the offices of Nabarro LLP at Lacon House, 84 Theobald's Road, London WC1X 8RW.

Copies of the 2010 Report & Accounts and the notice of AGM are also available on ValiRx's website at www.valirx.com.

For more information, please contact:

ValiRx plc	Tel: [phone]
Dr. Satu Vainikka
www.valirx.com
Cairn Financial Advisers LLP	Tel: [phone]
Nominated Adviser
Liam Murray / Avi Robinson
Hybridan LLP	Tel: [phone]
Broker
Claire Noyce
Peckwater PR
Tarquin Edwards	Tel: [phone]
	[e-mail]

Notes for Editors

ValiRx Plc

ValiRx Plc is a biopharmaceutical company developing novel technologies and products in oncology therapeutics and diagnostics. The product focus is in the epigenomic analysis and treatment of cancer, but the technologies can be applied to other fields as well, such as neurology and inflammatory diseases.

The Company listed on AIM in October 2006 and is creating a portfolio of innovative products through investment in specific development projects. It actively manages projects within this portfolio as a trading company and is not an investment vehicle. The ValiRx business model spreads the risks of life science technology developments by minimising financial exposure and running a set of projects to defined commercial endpoints. This maximises returns to shareholders by adding value at the earlier stages where value increases per investment unit are the greatest. 

The Company operates through the following divisional companies:

ValiMedix is the sales and distribution division of ValiRx

ValiPharma is the therapeutics division with two embedded technologies primarily directed at the treatment of cancers. Of particular note is GeneICE, ValiRx's technology for controlling rebellious genes, which was awarded a Eurostars grant to the value of €1.2 million to fund the development of the GeneICE products through preclinical stages in cancer treatments.  ValiRx is leading a consortium of biotechnology companies that are completing pre-clinical studies based on ValiRx's GeneIce technology platform, prior to entering clinical trials.

 

END

 

 

ACSABMTTMBTJBLB